Login / Signup

Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.

Yuji ShibataShuji Murakami
Published in: Expert opinion on drug safety (2020)
ICIs, including durvalumab, cause unique side effects, known as immune-mediated adverse events, which are commonly manageable with standard treatment algorithms. The safety profile of durvalumab monotherapy is similar to those of other PD-1/PD-L1 inhibitors. In the PACIFIC trial, durvalumab after radiotherapy resulted in a slight increase in pulmonary toxicity, but most cases were mild. The enhanced effect of ICIs when used in combination therapies is accompanied by an increased risk of side effects. Therefore, the authors evaluated the safety profile and risk-benefit balance of durvalumab combined with various agents.
Keyphrases
  • combination therapy
  • machine learning
  • pulmonary hypertension
  • radiation therapy
  • randomized controlled trial
  • squamous cell carcinoma
  • locally advanced
  • rectal cancer